NCT00727272View on ClinicalTrials.gov

A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions
Healthy
Interventions
DRUG

Quinine Sulfate Capsules 324 mg

One 324 mg capsule administered after an overnight fast of at least 10 hours.

DRUG

Quinine Sulphate Tablets 300 mg

One 300 mg tablet administered after an overnight fast of at least 10 hours.

DRUG

Quinine Sulfate Capsules 324 mg

One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.

Trial Locations (1)

56721

PRACS, Fargo

Sponsors
All Listed Sponsors
lead

Mutual Pharmaceutical Company, Inc.

INDUSTRY

NCT00727272 - A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions | Biotech Hunter | Biotech Hunter